Bausch Health Companies Inc

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Salix, Ortho Dermatologics and Diversified Products. The Bausch + Lomb/International segment consists of the sale of pharmaceutical products, over-the-counter products, and medical devices products. The Salix segment consists of sales in the U.S. of GI products. The Ortho Dermatologics segment consists of sales in the U.S. of Ortho Dermatologics (dermatological) products and global sales of Solta medical aesthetic devices. The Diversified Products segment consists of sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, in the U.S. of generic products, in the U.S. of dentistry products. The company was founded on March 29, 1994 and is headquartered in Laval, Canada.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, except for sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refers to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologic, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994, and is headquartered in Laval, Canada.

LAVAL, QC, Jan. 20, 2022 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") has announced that Dr. Yehia Hashad will join Bausch + Lomb Corporation ("Bausch + Lomb") as executive vice president of Research & Development (R&D) and chief medical officer (CMO) effective Jan. 31, 2022. Dr. Hashad will join Bausch + Lomb from Allergan/AbbVie, where for the past 11 years he held various roles, including leading Allergan's global clinical development program for its eye care portfolio.

Dr. Yehia Hashad Will Join Bausch + Lomb Corporation as Executive Vice President of Research & Development and Chief Medical Officer

LAVAL, QB, Jan. 18, 2022 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") announced today that it is seeking to refinance its existing credit agreement (the "Credit Agreement" and such refinancing, the "Credit Agreement Refinancing"). The refinanced Credit Agreement is expected to consist of approximately $2.5 billion of term B loans (the "New Term B Loans") and a $975 million revolving credit facility.

Bausch Health Announces It Is Seeking To Refinance Its Existing Credit Agreement And Conditional Redemption Of Existing Notes - These Steps Will Enable Bausch + Lomb IPO And Facilitate Full Separation

Bausch Health Companies Inc.'s ( BHC , Financial) plans to split into three public companies is pretty much a done deal, CEO Joseph Papa said at last week's J.P. Morgan Healthcare Conference.

Investors Will Have Opportunity to Invest in Bausch Spinoffs

Bausch + Lomb has filed to raise $100 million in an IPO, although the final figure may be significantly higher. Bausch + Lomb develops and sells eyecare products to consumers, pharmaceutical firms and surgical markets worldwide.

Bausch + Lomb Begins U.S. IPO Process

Bausch Health Companies ( BHC , Financial) ( TSX:BHC , Financial), which is dual listed in the U.S. and Canada, is planning on splitting into three companies this year - Bausch+Lomb, Solta Medical and Bausch Pharma. The main event is the Bausch+Lomb spinoff, in my view; it seems like the split is aimed at making Bausch+Lomb into an investment-worthy company.

Bausch Spins Forward to Unlock Value

Bausch (BHC) eye care business files for an initial public offering in the United States and Canada.

Bausch (BHC) Eye Care Business Files for IPO in the US & Canada

Bausch Health Companies Inc (NYSE:BHC) just said that its eye-care products unit Bausch + Lomb filed to go public on Thursday on both U.S. and Canadian exchanges via an initial public offering (IPO).

Bausch Health Spinoff Sends Stock Higher

Bausch & Lomb Corp filed S-1 for its initial public offering, nearly 1.5 years after its parent company, Bausch Health Companies Inc (NYSE: BHC) said it would spin off the eye-care company. The company said it plans to raise $100 million in its IPO.

Bausch Health's Eye-Care Spin-Off Entity Files For $100M IPO

Bausch & Lomb Corp. has filed for an initial public offering, according to a filing late Thursday. The Bausch Health Cos.

Bausch & Lomb files for IPO, parent Bausch Health to remain majority owner

LAVAL, QC and VAUGHAN, ON, Jan. 13, 2022 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") announced today that, in connection with its previously announced intention to separate its eye health business, its wholly owned subsidiary, Bausch + Lomb Corporation ("Bausch + Lomb"), has publicly filed a Registration Statement on Form S-1 with the U.S. Securities and Exchange Commission ("SEC") and a preliminary base post-receipt pricing procedure ("PREP") prospectus with the securities regulatory authorities in each of the provinces and territories of Canada (other than Quebec) ("Canadian Regulators") relating to a proposed initial public offering ("IPO") of Bausch + Lomb's common shares concurrently in the United States and Canada. All of the shares being offered will be sold by a wholly owned subsidiary of Bausch Health.

Bausch + Lomb Corporation Files Registration Statement and Preliminary Prospectus for Proposed Initial Public Offering

Bausch Health (BHC) closed the most recent trading day at $27.34, moving -1.51% from the previous trading session.

Bausch Health (BHC) Stock Sinks As Market Gains: What You Should Know

Bausch Health Companies, Inc. (BHC) CEO Joe Papa at 40th Annual J.P. Morgan Healthcare Conference (Transcript)

While we do not violate our overall cost basis lightly, we do believe the weakness thus far in 2022 is presenting an opportunity that we want to take advantage.

We're bulking up on this health-care name before it gets away from us

LAVAL, Quebec, Jan. 11, 2022 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") will provide a progress update on its business and strategic initiatives in a published presentation designed to complement remarks that will be provided by management at 9 a.m. ET tomorrow, Jan. 12, 2022, during a fireside chat at the 40th Annual J.P.

Bausch Health Will Provide Business And Strategic Update At The 40th Annual J.P. Morgan Healthcare Conference

Bausch has reduced net debt by some $5 billion since the worst of the turmoil in 2017. This makes a dent in leverage, certainly as the underlying business has stabilized.

Bausch Health: Getting Healthier, Gradually

Bausch Health Companies Inc. ( BHC , Financial) has traded in a low range for years, but that could soon change. The company is making progress on its research and recently announced a collaboration with the Glaucoma Research Foundation to raise awareness of hyperemia and how it may have an impact on the lives of patients with glaucoma.

Bausch Health Companies Is Doing Good and Doing Well

Chevron

Honeywell

Eli Lilly

Appearing on CNBC's "Halftime Report," Jim Cramer explained why Chevron, Eli Lilly, Honeywell and Bausch Health are some of his favorite stocks for the new year.

Here are 4 of Jim Cramer's top stock picks for 2022

Our reassessment comes ahead of the company's presentation at the annual J.P. Morgan Healthcare Conference next week.

We're increasing our price target on a club health stock

LAVAL, QC, Jan. 5, 2022 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) today announced that Joseph C. Papa, chairman and chief executive officer, is scheduled to participate at the 40th Annual J.P.

BAUSCH HEALTH TO PARTICIPATE AT THE 40TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

Bausch Health (BHC) closed the most recent trading day at $27.79, moving +0.65% from the previous trading session.

Bausch Health (BHC) Outpaces Stock Market Gains: What You Should Know

Data from a Post-Hoc Analysis Supports the Use of Salix's RELISTOR for Patients with Opioid-Induced Constipation and Advanced Illness in the Emergency Department Setting LAVAL, QC, Dec. 22, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) "Bausch Health" and its gastroenterology business, Salix Pharmaceuticals ("Salix"), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases, today announced that The Journal of Emergency Medicine has published a new post-hoc analysis of pooled results on the safety and efficacy of a single dose of RELISTOR® (methylnaltrexone bromide) injection in patients with severe illness and opioid-induced constipation (OIC) who had insufficient response to laxative therapy. Entitled, "First Dose Efficacy of Methylnaltrexone in Patients with Severe Medical Illness and Opioid-Induced Constipation: A Pooled Analysis," the study results demonstrated that an initial dose of RELISTOR injection effectively produced rescue-free laxation (RFL) in greater proportions of severely ill patients with OIC compared to placebo (61.4% within 4 hours vs.

RELISTOR® (METHYLNALTREXONE BROMIDE) DATA IS PUBLISHED IN THE JOURNAL OF EMERGENCY MEDICINE

The Mad Money host announced a new position in Bausch Health amid the spread of the omicron variant. Here's what you should know.

BHC Stock: 9 Things to Know as Jim Cramer Buys Bausch Health

Apple

AbbVie

Amazon

Alphabet

Morgan Stanley

Microsoft

Wells Fargo

There may be a lot of negativity out there. But for the Charitable Trust, we're staying the course and looking for opportunities.

Cramer's Investing Club: Here's a list of stocks you may want on your buying list

We believe a sum of the parts is greater than the whole analysis is a good case for buying shares of Bausch Health.

Cramer's Investing Club: We're starting a new trust position in a health stock

Following a reduction in the third quarter, Glenview Capital Management's Larry Robbins (Trades, Portfolio) disclosed earlier this week he boosted his stake in Bausch Health Companies Inc. ( BHC , Financial) by 9.13%.

News for Bausch Health Companies Inc Stock (BHC)